HCA VS GSK Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend

Performance

HCA
10/100

HCA returned 4.32% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

GSK
10/100

GSK returned 3.98% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

HCA
75/100

22 analysts offer 12-month price targets for HCA. Together, they have an average target of 265.95, the most optimistic target put HCA at 315 within 12-months and the most pessimistic has HCA at 200.

GSK
63/100

4 analysts offer 12-month price targets for GSK. Together, they have an average target of 0, the most optimistic target put GSK at 0 within 12-months and the most pessimistic has GSK at 0.

Technicals

HCA
50/100

HCA receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

GSK
10/100

GSK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

HCA
10/100

HCA has missed earnings 6 times in the last 20 quarters.

GSK
66/100

GSK has missed earnings 3 times in the last 20 quarters.

Profit

HCA
78/100

Out of the last 20 quarters, HCA has had 20 profitable quarters and has increased their profits year over year on 10 of them.

GSK
72/100

Out of the last 20 quarters, GSK has had 20 profitable quarters and has increased their profits year over year on 7 of them.

Volatility

HCA
49/100

HCA has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

GSK
56/100

GSK has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.

Dividend

HCA
23/100

HCA's most recent dividend was $0.35 per share, based on a share price of $237.58. It was a payout ratio of 11.37% compared to their total earnings.

GSK

"Dividend" not found for GSK

All score calculations are broken down here to help you make more informed investing decisions

HCA Healthcare, Inc. Summary

New York Stock Exchange / HCA
Healthcare
Medical - Care Facilities
HCA Healthcare, Inc., through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. It also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, the company operates psychiatric hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. As of December 31, 2021, it operated 182 hospitals, including 175 general and acute care hospitals, five psychiatric hospitals, and two rehabilitation hospitals; 125 freestanding surgery centers; and 21 freestanding endoscopy centers in 20 states and England. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.

GSK plc American Depositary Shares (Each representing two Ordinary Shares) Summary

New York Stock Exchange / GSK
Healthcare
Drug Manufacturers - General
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.